About AP-4 complex subunit mu-1
AP-4 complex subunit mu-1 (AP4M1) is a protein
from Homo sapiens identified by UniProt accession
O00189, 453 residues long.
MolForge cross-references it against 0 known binders and
95 disease associations.
Target properties
| Protein name | AP-4 complex subunit mu-1 |
| UniProt accession | O00189 |
| Gene | AP4M1 |
| Organism | Homo sapiens |
| Length | 453 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (95)
Diseases linked to this target (Open Targets).
- Severe intellectual disability and progressive spastic paraplegia · score 0.75
- Spastic paraplegia · score 0.71
- Intellectual disability · score 0.49
- neurodegenerative disease · score 0.48
- AP-4 deficiency syndrome · score 0.44
- hereditary spastic paraplegia · score 0.41
- genetic disorder · score 0.41
- Abnormality of the nervous system · score 0.34
- Microcephaly · score 0.26
- Global developmental delay · score 0.26
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O00189-F1 | alphafold | PREDICTED | 85.44 | — |
Amino-acid sequence (453 residues)
MISQFFILSS KGDPLIYKDF RGDSGGRDVA ELFYRKLTGL PGDESPVVMH HHGRHFIHIR HSGLYLVVTT SENVSPFSLL ELLSRLATLL GDYCGSLGEG TISRNVALVY ELLDEVLDYG YVQTTSTEML RNFIQTEAVV SKPFSLFDLS SVGLFGAETQ QSKVAPSSAA SRPVLSSRSD QSQKNEVFLD VVERLSVLIA SNGSLLKVDV QGEIRLKSFL PSGSEMRIGL TEEFCVGKSE LRGYGPGIRV DEVSFHSSVN LDEFESHRIL RLQPPQGELT VMRYQLSDDL PSPLPFRLFP SVQWDRGSGR LQVYLKLRCD LLSKSQALNV RLHLPLPRGV VSLSQELSSP EQKAELAEGA LRWDLPRVQG GSQLSGLFQM DVPGPPGPPS HGLSTSASPL GLGPASLSFE LPRHTCSGLQ VRFLRLAFRP CGNANPHKWV RHLSHSDAYV IRI
Explore AP-4 complex subunit mu-1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets